Gilead Announces Latest Data in Ongoing HIV Cure Research Program
Gilead Sciences, Inc. (NASDAQ: GILD) today presented results from two studies of investigational toll-like receptor 7 (TLR7) agonists as part of an HIV cure research program. The Phase 1 and preclinical study results demonstrate that the TLR7 agonists vesatolimod (GS-9620) and GS-986 can induce immune activation and follow earlier preclinical research suggesting that TLR7 agonists can potentially lead to viral remission, as part of combination regimens. The HIV viral reservoir is present even in virologically suppressed individuals and its elimination is regarded as a main obstacle to achieving a cure. The data were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) being held in Mexico City.
“While treatments have improved dramatically, people living with HIV still face a lifetime of therapy and potential complications. That reality drives our ongoing pursuit of a cure for HIV,” said Diana Brainard, MD, Senior Vice President, HIV and Emerging Viruses, Gilead Sciences. “These findings demonstrate that TLR7 agonists have a potential role to play in scalable strategies for achieving sustained viral remission in humans, and we will continue to evaluate these agents as part of investigational curative regimens.”
Studies on TLR7 agonists presented at IAS include:
Oral presentation WEAA0304: Vesatolimod (GS-9620) is safe and pharmacodynamically active in HIV-infected individuals
This double-blind, placebo-controlled Phase 1 clinical study enrolled 48 people living with HIV on antiretroviral therapy. The median age of the participants in this study was 47 years (43 were male), with a median of 8.1 years of therapy. In the study, 36 participants received escalating doses of vesatolimod (1-12 mg) and 12 received placebo every other week. Vesatolimod at higher doses stimulated a range of immune responses. Vesatolimod was well-tolerated at all doses, with no drug-related Grade 3 or 4 adverse events, no related serious adverse events and no adverse events leading to study drug discontinuation. Study drug-related adverse events including mild, transient flu-like symptoms were observed in 9 of 36 participants at doses of 2 mg and higher, consistent with previous trials. These symptoms resolved within one day and did not occur with each dose.
“This study demonstrates that vesatolimod can be administered to people living with HIV at doses that may have immune effect and are well-tolerated. The results support studies into the potential role of vesatolimod as part of combination regimens aimed at achieving ART-free control of HIV,” said Sharon A. Riddler, MD, Director of Clinical Research in the Infectious Diseases Division, University of Pittsburgh School of Medicine, one of the study principal investigators.
Oral presentation WEAA0105: Oral TLR7 agonist administration induces an immunostimulatory response in SIV-infected ART-suppressed infant rhesus macaques
This preclinical study evaluated the oral administration of GS-986 in two simian immunodeficiency virus (SIV)-infected, virologically suppressed rhesus macaques. At seven months of age, both macaques were administered 0.1 mg of GS-986 orally. Four weeks later, a second 0.3 mg dose was administered, and in both instances blood count, viral loads, cytokine concentrations and immune response were monitored. At both the 0.1 mg and 0.3 mg dose levels, GS-986 induced immune system activation with observed increases in peripheral plasma cytokines/chemokines and activation of immune cells. GS-986 was well-tolerated with normal complete blood count and maintenance of viral suppression.
These results add new information to the existing preclinical data on GS-986 for the potential future application of an oral TLR7 agonist in people living with HIV.
Vesatolimod and GS-986 are investigational compounds and are not approved by the U.S. Food and Drug Administration or any other regulatory authority. Their safety and efficacy have not been established.
There is no cure for HIV infection or AIDS.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For nearly 30 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention, testing and linkage to care, and cure research. Today, it is estimated that more than 12 million people living with HIV globally receive antiretroviral therapy provided by Gilead or one of the company’s manufacturing partners.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from ongoing and additional clinical trials involving GS-9620 and GS-986. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Sung Lee, Investors
Ryan McKeel, Media
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems’ Acceleration Fund Announces Launch of The Cohesive Companies, Advancing Infrastructure Digital Twins to Improve Asset Performance13.7.2020 16:01:00 CEST | Press release
Bentley Systems, Incorporated, a leading global provider of comprehensive software and digital twins services for advancing the design, construction, and operations of infrastructure, today announced that its Acceleration Fund has launched The Cohesive Companies, a wholly owned subsidiary, anchored by the acquisition of Atlanta-based Cohesive Solutions. The new business venture will include the services team from Bentley’s AssetWise business and the offerings of Bentley, Cohesive, and IBM’s Maximo to support the digital transformation of infrastructure owner-operators. The Cohesive Companies will act as a digital integrator to help infrastructure asset owners upgrade their enterprise environments to leverage digital twins—digital representations and simulations of a physical asset, synchronizing digital context (current existing conditions), digital components (engineering content), and digital chronology (lifecycle change management). Infrastructure digital twins can empower asset ope
Project Management Institute Announces List of 50 Next Generation Leaders to Watch13.7.2020 15:00:00 CEST | Press release
Project Management Institute (PMI) today announced its first annual Future 50 list, which features the 50 next generation leaders that are creating, building, and transforming the world through notable projects. The 50 young standout project leaders highlighted in the specially dedicated July/August issue of https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.pmnetwork-digital.com%2Fpmnetwork%2Fjuly_august_2020&esheet=52248039&newsitemid=20200713005075&lan=en-US&anchor=PM+Network%26%23174%3B+magazine&index=1&md5=b87a3fa432ccbcdd2816b3ede58c905c PM Network® magazine represent the wave of change and talent around the globe—a youthquake that will reshape the future and accelerate innovation in the here and now. Honorees include groundbreaking achievements from people across a variety of industries and countries, including Director Greta Gerwig, Laura Jones from the Special Olympics and Miishe Addy from Jetstream Africa. This press release features multimedia. View the fu
Become a Pet Trainer in the Newest Mabinogi “P.E.T.” Update Arriving on July 1613.7.2020 15:00:00 CEST | Press release
Mabinogi,Nexon’s free-to-play fantasy MMORPG will be receiving the delightful new “P.E.T.” update on July 16! Following the introduction of Mabinogi’s exciting furry pets in the “My Little Pet” update, the World of Erinn is changing with the addition of more powerful Fynn Pets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005083/en/ Mabinogi P.E.T. (Graphic: Business Wire) While the recent “My Little Pet” update expanded activities for pets embarking on expeditions to explore the world of Erinn, the P.E.T. update challenges players with a new Pet Training talent to discover the Power of the Fynn and set out to unlock stronger Fynn Pets. To unlock Fynn Pets, players need to sync their main pet with other pets using Fynn Sync. The Fynn Pet will receive the Power of the Fynn, increasing a pet’s max level, inventory, summoning time and more! With the update, players can also defeat monsters to obtain Fynni Gems and bloom
Rimini Street Appoints Gerard Brossard as COO13.7.2020 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced the appointment of Gerard Brossard to the newly created role of executive vice president and chief operating officer (COO). Brossard is responsible for Rimini Street’s global field operations and the global sales and success of the Company’s Support and Application Management Services for Oracle and SAP products. Brossard reports directly to Rimini Street CEO, Seth A. Ravin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005192/en/ Rimini Street Appoints Gerard Brossard as COO (Photo: Business Wire) New COO Brings Proven Capabilities to Support Accelerating Company Growth Prior to joining Rimini Street, Brossard served as executive vice president and general manager of Rackspace’s Global Solutions and S
Aeolus Announces Appointment of Aditya Dutt as Partner and President13.7.2020 14:00:00 CEST | Press release
Aeolus Capital Management Ltd. (“Aeolus”) today announces that Aditya Dutt will be appointed a Partner and President of Aeolus and will be elected as a member of the Aeolus Board, following a period of gardening leave from RenaissanceRe Holdings (“RenaissanceRe”), his current employer. Mr. Dutt is currently Senior Vice President of RenaissanceRe and President of Renaissance Underwriting Managers, Ltd. In these capacities, Mr. Dutt leads RenaissanceRe’s Insurance Linked Securities and third party capital management businesses, including DaVinci Re, Top Layer Re, Upsilon Fund, Medici Fund, Vermeer Re and the Langhorne Re joint venture with the Reinsurance Group of America. Additionally, Mr. Dutt also manages RenaissanceRe’s portfolio of strategic investments. Mr. Dutt was previously RenaissanceRe’s Corporate Treasurer and Head of Investor Relations. Prior to joining RenaissanceRe, Mr. Dutt was an investment banker at Morgan Stanley and Salomon Brothers. Since early 2017, Aeolus has been
New Data to Be Presented at the ISTH 2020 Virtual Congress Demonstrating Octapharma’s Commitment to Patients With Bleeding Disorders13.7.2020 13:37:00 CEST | Press release
Octapharma announced today that new research findings from its haematology portfolio will be presented at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress, taking place on 12–14 July 2020. The NuProtect study (NCT01712438) investigated the immunogenicity, efficacy and safety of Nuwiq® (simoctocog alfa) in 108 previously untreated patients with haemophilia A. The final results of the study showed a cumulative incidence of high-titre anti-FVIII inhibitors of 17.6%. Patients who completed the NuProtect study were offered participation in a long-term extension study (NCT01992549). The results of the extension study will be presented for the first time at ISTH 2020. In patients who develop inhibitors, immune tolerance induction (ITI) with repeated FVIII administration is the only proven approach to eradicate inhibitors. Three posters will be presented at ISTH 2020 reporting on the success of ITI with two of Octapharma’s FVIII products, octanate® and N